UK To Offer Non-AstraZeneca Covid-19 Vaccine To Under-30s Ov
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
The U.K. recommended not using AstraZeneca Plc’s Covid-19 vaccine on those under the age of 30 after drug regulators there and in the European Union highlighted a possible link with a rare type of blood clot in the brain. The assessments follow an increasing number of reports of side effects in people who’ve received the Astra dose.

In its latest recommendation, the European Medicines Agency said that “unusual blood clots with low blood platelets should be listed as very rare side effects.” The U.K. is advising that those under 30 be offered an alternative to Astra if one is available. The latest assessments of the Astra vaccine, comes amid increasing public wariness about the shot, with patients from Bucharest to Calais canceling scheduled appointments as they await more clarity.

EMA Executive Director Emer Cooke tried to counter any public worries by pointing out that the vaccine is vital in fighting a virus that’s causing thousands of deaths every day. Covid-19 is a very serious disease with high hospitalization and death rates. This vaccine has proven to be highly effective. It prevents severe disease and hospitalization and it is saving lives.

Concerns about the vaccine are centered on an unusual type of blood clot in the brain called cerebral venous sinus thrombosis. It has occurred together with low levels of blood platelets after vaccination. The EMA’s safety committee based its latest analysis on a review of 84 cases of clotting, with most to the brain area, that had been reported by March 22. By April 4, the reported clotting instances had increased to 222 again, with most to the brain area out of 34 million people who’d received the shot.

1 share